Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - FENNEC PHARMACEUTICALS INC. | v236780_ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of report (Date of earliest event reported) October 7, 2011
|
Adherex Technologies Inc.
|
|
(Exact Name of Registrant as Specified in Its
Charter)
|
|
Canada
|
001-32295
|
20-0442384
|
||
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
PO Box 13628, 68 TW Alexander Drive, Research Triangle Park, North Carolina 27709
(Address of Principal Executive Offices) (Zip Code)
919-636-4530
(Registrant’s Telephone Number, Including Area Code)
Not applicable.
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01 Other Events
On October 7, 2011, Adherex Technologies, Inc. (the “Company”) issued a press release to announce a meeting with the FDA’s Pediatric Subcommittee of the Oncologic Drugs Advisory Committee which will discuss the development of Sodium Thiosulfate Injection, USP, 25% (STS) on November 1, 2011. The full text of the press release is furnished as Exhibit 99.1.
Exhibits
99.1 Press Release issued by Adherex Technologies, Inc. dated October 7, 2011.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
Dated: October 7, 2011
|
Adherex Technologies Inc.
|
||
|
By:
|
/s/ Robert Andrade
|
||
|
Chief Financial Officer
|
|||